M Yadagiri1, A Robinson2, K Darzy3, P Winocour3, A Strzelecka4, I W Gallen5, A Bickerton6, A Evans7, R E J Ryder1 and ABCD nationwide canagliflozin audit contributors8
1Sandwell and West Birmingham NHS Trust, Birmingham, UK
2Royal United Hospital, Bath, UK
The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in research projects including all fields of General Internal Medicine, particularly polymorbidity and other common I.M. conditions.
Up to 17,500 Euros is available, to be awarded for a maximum study period of 1 year. Deadline for Receipt of Applications is 15 July 2020.
People with type 1 diabetes who are taking SGLT-2 inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin and Ertugliflozin) are at risk of developing diabetic ketoacidosis during any illness. During the Coronavirus epidemic there are some additional safety considerations in treating DKA in patients with COVID-19. In the absence of high quality evidence to guide us, ABCD believes that clinicians may wish to discuss these medications with their patients and possibly mutually agree to stop SGLT-2 inhibitors and control blood glucose by adjusting insulin doses.
We are currently seeking applications for two new ABCD committee members.
All members of ABCD are eligible for application and should be proposed and seconded by other current members of ABCD.
To apply simply complete the online form, the closing date is Wednesday 3rd June 2020.
A National Stakeholders Covid-19 Response Group Interim Guidance developed by JBDS-IP, ABCD, Diabetes UK and diabetes FRAIL
This guidance is designed to support clinical decision-making in care.
Practical guidance for managing inpatient hyperglycaemia during COVID-19
Concise advice on inpatient diabetes during COVID-19 - A guideline for managing DKA using subcutaneous insulin where intravenous insulin infusion is not possible.
REJ Ryder on behalf of the ABCD Exenatide Audit Contributors
City Hospital, Birmingham, UK
A National Stakeholders Covid-19 Response Group Interim Guidance developed by JBDS-IP, ABCD, Diabetes UK and diabetes FRAIL
This guidance is designed to support clinical decision-making in care homes. As such, the guidance will take into account the availability of skilled personnel, access to monitoring of blood glucose (sugar) and ketones, fluid administration limits, and overall level of care likely to be available.
This guidance was prepared by a multidisciplinary stakeholder group in order to:
